Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Blood (2024) 144 (18): 1924–1935.

https://doi.org/10.1182/blood.2024024631

Published: 2024

Includes: Supplemental data

Journal Articles

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Blood (2024) 144 (3): 272–282.

https://doi.org/10.1182/blood.2023022730

Published: 2024

Includes: Supplemental data

Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Blood (2023) 142 (Supplement 1): 4639.

https://doi.org/10.1182/blood-2023-188827

Published: 2023

Journal Articles

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

Andrea Visentin, Enrico Gaffo, Moritz Furstenau, Jennifer A. Woyach, Panagiotis Baliakas, Kerry A Rogers, Cecelia Miller, Claudia Haferlach, Karla Plevova, David Graham Oscier, Zadie Davis, Florence Nguyen Khac, Eleonora Roncaglia, Gian Matteo Rigolin, Anastasia Athanasiadou, Fanny Baran-Marszak, Alberto Valiente, Maria Jose Terol, Pau Abrisqueta, Blanca Espinet, Anna Puiggros, Annalisa Martines, Laura Bonaldi, Francesca Romana Mauro, Lydia Scarfo, Thomas Chatzikonstantinou, Eugen Tausch, Karl Anton Kreuzer, Arnon P. Kater, Francesc Bosch, Michael Doubek, Panayiotis Panayiotidis, Olga Kalashnikova, Federica Frezzato, Monica Facco, Valeria Ruocco, Alessia Buratin, Silvia Orsi, Alessandro Cellini, Francesco Angotzi, Chiara Adele Cavarretta, Ivan Zatta, Andrea Serafin, Robin Foa, Barbara F. Eichhorst, Antonio Cuneo, Kostas Stamatopoulos, Paolo Ghia, Stefania Bortoluzzi, Livio Trentin

Blood (2023) 142 (Supplement 1): 3275.

https://doi.org/10.1182/blood-2023-174569

Published: 2023

Journal Articles

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Blood (2023) 142 (Supplement 1): 203.

https://doi.org/10.1182/blood-2023-173708

Published: 2023

Journal Articles

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Blood (2023) 142 (Supplement 1): 1897.

https://doi.org/10.1182/blood-2023-173707

Published: 2023

Journal Articles

Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

Guillermo Garcia-Manero, Olatoyosi Odenike, Shaun Fleming, Gail J. Roboz, Meagan Jacoby, Ilona Cunningham, Karl-Anton Kreuzer, Anoop K Enjeti, Maria R. Baer, Rachel Cook, Joseph Jurcic, Grace Ku, Ying Zhou, David Hoffman, Jalaja Potluri, Jacqueline S. Garcia

Blood (2023) 142 (Supplement 1): 1868.

https://doi.org/10.1182/blood-2023-187102

Published: 2023

Journal Articles

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

Blood (2023) 142 (Supplement 1): 204.

https://doi.org/10.1182/blood-2023-188705

Published: 2023

Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Blood (2023) 142 (Supplement 1): 635.

https://doi.org/10.1182/blood-2023-173709

Published: 2023

Journal Articles

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Blood (2023) 142 (11): 961–972.

https://doi.org/10.1182/blood.2023020013

Published: 2023

Includes: Supplemental data

Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater

Blood (2023) 142 (5): 446–459.

https://doi.org/10.1182/blood.2023019634

Published: 2023

Includes: Supplemental data

Journal Articles

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL

Blood (2023) 141 (12): 1425–1441.

https://doi.org/10.1182/blood.2022015494

Published: 2023

Includes: Supplemental data

Journal Articles

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Blood (2022) 140 (Supplement 1): 842–845.

https://doi.org/10.1182/blood-2022-164786

Published: 2022

Journal Articles

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Blood (2022) 140 (Supplement 1): 839–841.

https://doi.org/10.1182/blood-2022-163775

Published: 2022

Journal Articles

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Blood (2022) 139 (2): 177–187.

https://doi.org/10.1182/blood.2021010845

Published: 2022

Includes: Supplemental data

Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Blood (2021) 138 (Supplement 1): 71.

https://doi.org/10.1182/blood-2021-146161

Published: 2021

Journal Articles

Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)

Blood (2020) 136 (Supplement 1): 21–23.

https://doi.org/10.1182/blood-2020-134827

Published: 2020

Journal Articles

Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Cameron Wilson, Maneesh Tandon, MD, Travers Ching, Anna-Maria Fink, MD, Matthias Ritgen, MD, Eugen Tausch, MD, Karl-Anton Kreuzer, MD, William Schary, PhD, Clemens-Martin Wendtner, Barbara Eichhorst, MD, Stephan Stilgenbauer, MD, Yanwen Jiang, Michael Hallek, Kirsten Fischer, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-136977

Published: 2020

Journal Articles

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136957

Published: 2020

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

NARROW

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

Tislelizumab Plus Zanubrutinib in Patients with Richter Transformation: Primary Endpoint Analysis of the Prospective, Multi-Center, Phase-II RT1 Trial of the German CLL Study Group

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)

Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial

Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only